Tag: cases

Timing Watch & Jewelry Limited expands its retail portfolio, highlighting exclusive Swiss collections from heritage brand Juvet and racing-inspired Daumier

NEW YORK, June 19, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Verra Mobility Corporation (NASDAQ: VRRM) between February 24, 2026 and May 26, 2026, inclusive (the “Class Period”), of the important August 4, 2026 lead plaintiff deadline.

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Commvault Systems, Inc. (NASDAQ: CVLT) between April 29, 2025 and January 26, 2026, inclusive (the “Class Period”), of the important July 17, 2026 lead plaintiff deadline.

Trading Symbol: TSX/NYSE American: SVMVANCOUVER, BC, June 18, 2026 /CNW/ - Silvercorp Metals Inc. ("Silvercorp" or the "Company") (TSX: SVM) (NYSE American: SVM) announces that,...

Trading Symbol: TSX/NYSE American: SVMVANCOUVER, BC, June 18, 2026 /PRNewswire/ - Silvercorp Metals Inc. ("Silvercorp" or the "Company") (TSX: SVM) (NYSE American: SVM) announces that,...

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline.

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Graphic Packaging Holding Company (NYSE: GPK) between February 4, 2025 and February 2, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.

The case alleges that the IPO’s offering documents contained misleading statements and/or omitted material information.

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome.

Jiangsu, China, June 18, 2026 (GLOBE NEWSWIRE) -- Mingteng International Corporation Inc. (Nasdaq: MTEN) (the “Company”) today announced the closing of its previously announced registered direct offering of 1.48 million Class A ordinary shares, par value $0.00005 per share (“Class A Ordinary Shares”), at a purchase price of $2.00 per share, and pre-funded warrants to purchase Class A Ordinary Shares at an original exercise price of $2.00, with $1.99995 of the original exercise price pre-funded at the closing, and a remaining exercise price of $0.00005 per Class A Ordinary Share.  In a concurrent private placement, the Company also issued to the same investors unregistered warrants to purchase up to 1.48 million Class A Ordinary Shares (the “Private Warrants”), at an exercise price of $2.00 per Class A Ordinary Share. The Private Warrants are exercisable from the closing and will expire 18 months from the date of issuance.

MUNICH, June 19, 2026 /PRNewswire/ -- The District Court Munich, Germany (Landgericht München I) today ruled in favor of Infineon Technologies in two further...

MUNICH, June 18, 2026 /PRNewswire/ -- The District Court Munich, Germany (Landgericht München I) today ruled in favor of Infineon Technologies in two further...

MUNICH, June 18, 2026 /PRNewswire/ -- The District Court Munich, Germany (Landgericht München I) today ruled in favor of Infineon Technologies in two further...

MUNICH, June 18, 2026 /CNW/ -- The District Court Munich, Germany (Landgericht München I) today ruled in favor of Infineon Technologies in two further...